Pharmaceutical - Oncology

Filter

Current filters:

Oncology

Popular Filters

1 to 25 of 1200 results

New indication for Astellas/Medivation’s Xtandi from US FDA

New indication for Astellas/Medivation’s Xtandi from US FDA

11-09-2014

The US Food and Drug Administration has approved a new indication for the use of Japanese drug major…

Astellas PharmaMedivationOncologyPharmaceuticalResearchUSAXtandi

Bristol-Myers Squibb and Ono Pharma sue Merck over Keytruda

Bristol-Myers Squibb and Ono Pharma sue Merck over Keytruda

08-09-2014

US drug major Bristol-Myers Squibb and partner Japan’s Ono Pharmaceutical have filed a law suit against…

Advanced melanomaBristol-Myers SquibbIpilimumabKeytrudaLaw suitLegalMerck & CoOncologyOno PharmaceuticalPharmaceuticalUSA

Karolinska Development appoints Bruno Lucidi as chief executive of KDev Oncology

Karolinska Development appoints Bruno Lucidi as chief executive of KDev Oncology

08-09-2014

Swedish drug developer Karolinska Development has appointed Bruno Lucidi as chief executive of the wholly-owned…

Akinion PharmaceuticalsBoardroomBruno LucidiKarolinska DevelopmentKDev OncologyOncologyPharmaceuticalSweden

Astellas' isavuconazole NDA accepted by US FDA

Astellas' isavuconazole NDA accepted by US FDA

08-09-2014

The US Food and Drug Administration has accepted a New Drug Application filing by Japanese drug major…

Astellas PharmaFungal diseasesInvasive aspergillosisInvasive mucormycosisisavuconazoleOncologyPharmaceuticalRegulationUSA

Chugai launches ALK inhibitor Alecensa in Japan

Chugai launches ALK inhibitor Alecensa in Japan

07-09-2014

Japanese drugmaker Chugai Pharmaceutical said on Friday that it has launched the ALK inhibitor Alecensa…

AlecensaalectinibChugai PharmaceuticalJapanMarkets & MarketingOncologyPharmaceuticalRoche

Sellas Life Sciences gains WT1 cancer vaccine rights from Memorial Sloan Kettering

Sellas Life Sciences gains WT1 cancer vaccine rights from Memorial Sloan Kettering

05-09-2014

Swiss/Greek pharmaceutical and clinical research group Sellas Life Sciences Group has signed an exclusive…

GlobalLicensingOncologyPharmaceuticalSellas Life SciencesVaccines

Breast cancer has Pharma’s largest and most innovative drug pipeline; report

Breast cancer has Pharma’s largest and most innovative drug pipeline; report

05-09-2014

The breast cancer therapeutics pipeline boasts a high degree of innovation in first-in-class molecules,…

OncologyPharmaceuticalResearch

Merck & Co’s melanoma drug Keytruda becomes first FDA-approved anti-PD-1 therapy

Merck & Co’s melanoma drug Keytruda becomes first FDA-approved anti-PD-1 therapy

05-09-2014

The US Food and Drug Administration has granted accelerated approval for pharma giant Merck & Co’s…

KeytrudaMerck & CoOncologypembrolizumabPharmaceuticalRegulationUSA

Redx Pharma and AstraZeneca collaborate on oncology research

04-09-2014

UK-based drug discovery firm Redx Pharma says it has entered into a research collaboration with Anglo-Swedish…

AstraZenecaOncologyPharmaceuticalRedx PharmaResearch

Infinity and AbbVie collaborate on duvelisib in deal worth up to $805 million

Infinity and AbbVie collaborate on duvelisib in deal worth up to $805 million

03-09-2014

US drug discovery firm Infinity Pharmaceuticals has entered into a global collaboration with AbbVie to…

AbbVieduvelisibInfinity PharmaceuticalsIPI-145LicensingOncologyPharmaceutical

Ipsen receives priority review for sNDA for Somatuline

Ipsen receives priority review for sNDA for Somatuline

01-09-2014

French drugmaker Ipsen has received priority review for its supplemental New Drug Application from the…

Gastroenteropancreatic neuroendocrine tumorsIpsenOncologyPharmaceuticalRegulationSomatulineUS Food and Drug AdministrationUSA

Colorectal cancer market will remain steady at $7.7 billion by 2023; report

29-08-2014

The market for colorectal cancer (CRC) therapies will remain constant, at around $7.7 billion by 2023…

EuropeJapanMarkets & MarketingOncologyPharmaceuticalUSA

Tau Therapeutics and Xdynia merge to form Cavion

29-08-2014

Privately-held US drugmakers Tau Therapeutics and Xdynia announced today that they have merged; the surviving…

CavionMergers & AcquisitionsNeurologicalOncologyPharmaceuticalTau TherapeuticsXdynia

Edison re-evaluates Onconova based on extended rigosertib timeline after trial failure

Edison re-evaluates Onconova based on extended rigosertib timeline after trial failure

29-08-2014

After failing to meet the primary endpoint of its trial of rigosertib (IV), oncology specialist Onconova…

FinancialMyelodysplastic syndromeOncologyOncology specialistOnconova TherapeuticsPharmaceuticalrigosertibUSA

NHS England boosts the Cancer Drugs Fund for more access to innovative medicines

NHS England boosts the Cancer Drugs Fund for more access to innovative medicines

28-08-2014

The National Health Service England has pledged to boost the Cancer Drugs Fund by £160 million ($265…

Cancer Drugs FundNHS EnglandOncologyPharmaceuticalRegulationUK

BTG and SciClone's DC Bead liver cancer therapy approved in China

BTG and SciClone's DC Bead liver cancer therapy approved in China

28-08-2014

UK specialist health care company BTG and its partner, China-focused US specialty drugmaker SciClone…

BTGChinaDC BeadHepatologyOncologyPharmaceuticalSciClone PharmaSciClone Pharmaceuticals

Pfizer and Merck to explore potential of Xalkori/pembrolizumab combo

Pfizer and Merck to explore potential of Xalkori/pembrolizumab combo

26-08-2014

US pharma giants Pfizer and Merck & Co have inked an agreement to explore the therapeutic potential of…

Merck & CoOncologypembrolizumabPfizerPharmaceuticalResearchXalkori

Recipharm inks deal with Isofol Medical on Modufolin

Recipharm inks deal with Isofol Medical on Modufolin

26-08-2014

Swedish contract development and manufacturing group Recipharm and Isofol Medical AB, a Gothenburg-based…

FinancialIsofol MedicalModufolinOncologyPharmaceuticalProductionRecipharmResearch

IQWiG finds added benefit for Novartis’ Jakavi in myelofibrosis

IQWiG finds added benefit for Novartis’ Jakavi in myelofibrosis

20-08-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products,…

Federal Joint CommitteeGermanyJakaviMyelofibrosisNovartisOncologyPharmaceuticalPricingRare diseasesRegulation

Clinigen adds to oncology portfolio with AstraZeneca’s Ethyol

Clinigen adds to oncology portfolio with AstraZeneca’s Ethyol

20-08-2014

UK-based Clinigen Group has acquired the global rights to the oncology support therapy Ethyol (amifostine)…

ClinigenClinigen GroupEthyolLicensingOncologyPharmaceuticalTreatment for head and neck cancerUK

Novartis to start production of Tasigna in Russia

Novartis to start production of Tasigna in Russia

19-08-2014

Russia’s largest drugmaker Pharmstandard has signed an agreement with Swiss pharma major Novartis on…

CancerCytokinesHealth Medical PharmaIgor KrylovMajorNovartisOncologyPharmaceuticalPharmstandardProductionRussiaTasigna

1 to 25 of 1200 results

Back to top